Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes - Heise, T.; Hermanski, L.; Nosek, L.; Feldman, A.; Rasmussen, S.; Haahr, H. (Diabetes, obesity & metabolism, 2012)
Keywords: Adolescent; Adult; Aged; Area Under Curve; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - drug therapy; Double-Blind Method; Female; Glucose; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - pharmacology; Insulin; insulin degludec; Insulin Glargine; Insulin, Long-Acting - adverse effects; Insulin, Long-Acting - pharmacology; Male; Middle Aged; Pharmacodynamics; pharmacokinetics; type 1 diabetes; Young Adult